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Abstract
Background: Aging and insulin resistance have been related to reduced mitochondrial function and oxidative stress.
Muscular phosphodiesters (PDE) are comprised of metabolites of phospholipid breakdown and may reflect membrane
damage. We aimed to test the hypothesis that myocellular PDE are increased in patients with type 2 diabetes (T2D) and
correlate inversely with mitochondrial ATP turnover.
Methods: A Cross-sectional study in the Clinical Research Facility of an University hospital was performed. 10 nonobese
middle-aged patients with T2D, 10 healthy humans matched for sex, age and physical activity index (CONm) and 18 young
healthy humans (CONy) were included. Myocellular PDE and unidirectional flux through ATP synthase (fATP) were measured
with
31P magnetic resonance spectroscopy (MRS). Intramyocellular (IMCL) and hepatocellular lipid deposition (HCL) were
quantified with
1H MRS. Insulin sensitivity (Rd) was assessed from hyperinsulinemic-euglycemic clamp tests in 10 T2D, 10
CONm and 11 CONy.
Results: During fasting, T2D and CONm had 1.5 fold greater PDE than CONy (2.860.2, 2.560.2, 1.760.1 mmol/l, P=0.004).
Stimulation by insulin did not affect PDE in any group. PDE correlated negatively with Rd (r=20.552, p,0.005) and fATP
(r=20.396, p,0.05) and positively with age (r=0.656, p,0.001) and body mass (r=0.597, p,0.001). PDE also related
positively to HbA1c (r=0.674, p,0.001) and fasting plasma glucose (r=0.629, p,0.001) within T2D and across all
participants.
Conclusions: Muscular PDE concentrations associate with age, lower resting mitochondrial activity and insulin resistance,
which is determined mainly by body mass and glycemia.
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Introduction
Type 2 diabetes mellitus (T2D) represents one of the world’s
greatest economic and health care challenges. T2D results from an
imbalance between insulin responsiveness and insulin secretion.
Skeletal muscle is mainly responsible for whole-body insulin
resistance and determines substrate oxidation particularly during
exercise. Reduced mitochondrial oxidative capacity, activity and/
or content have been related to aging, intramyocelluar lipid
content (IMCL) and muscular insulin resistance [1,2,3,4].
It has been hypothesized that aging-associated insulin
resistance results from cumulative free radical damage leading
to lower mitochondrial function and increased IMCL [5]. Of
note, preventing oxidative damage by overexpression of
antioxidant defense mechanisms indeed protected rodent models
from lipid-induced and age-associated insulin resistance [5,6].
However, a causal relationship between aging, mitochondria and
the development of T2D has been questioned [1,7,8]. Of note,
there is no evidence for disruption of the cellular integrity and
contractile function in skeletal muscle of T2D, while patients
with myopathies can exhibit mitochondrial abnormalities and
insulin resistance [9,10,11].
Membrane phospholipids are hydrolyzed to free fatty acids
(FFA) and phosphodiesters (PDE) which are regarded as cell
membrane degradation products [12]. Myocellular PDE are
elevated in patients with myopathies [13,14] and in elderly
[15,16] and increase in response to treatment with statins [17].
PDE may reflect fiber atrophy, accumulated sarcolemmal damage
[18] or structural and functional changes during loss of muscle
mass possibly resulting from cumulative oxidative damage [19].
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21846Thus, PDE may serve as marker of biomembrane integrity
[18,20]. The relationship between PDE content and mitochon-
drial function and insulin sensitivity in healthy middle-aged
humans and in patients with T2D has not yet been reported.
We hypothesized that T2D have elevated myocellular PDE
which relates to age, mitochondrial activity and insulin sensitivity.
Thus, we measured PDE, unidirectional flux through ATP
synthase (fATP) during fasting and insulin stimulation as a marker
of resting mitochondrial activity [21,22], insulin stimulated
glucose-6-phosphate (DG6P) as a marker of insulin-stimulated
glucose transport/phosphorylation, whole-body glucose disposal
(Rd) and endogenous glucose production (EGP) in T2D, non-
diabetic age-matched (CONm) and younger humans (CONy).
Methods
Ethics Statement
All studies were carried out in accordance with the most-recent
version of the Declaration of Helsinki and approved by the local
ethics committee of the Medical University of Vienna. Informed
written consent has been obtained from all participants.
Subjects
Ten T2D, 10 CONm matched for sex, age and physical activity
and 18 CONy were included. PDE content in all participants from
one study [22] and 7 controls from another study [23] are
reported. They underwent complete medical history, clinical
examination and lab tests. All participants had comparable
physical activity according to Baeckes questionnaire, refrained
from any physical exercise for three days and fasted for 12 h
before the study. T2D had neither islet cell antibodies nor signs of
neurological disorders including diabetes-related neuropathy.
Only sulfonylurea and/or metformin were allowed as glucose-
lowering medication but withdrawn three days before the study.
Four T2D and none of the healthy participants received statins,
which were not withdrawn before the study. Control subjects had
no family history of T2D.
Experimental Protocol
After baseline blood sampling, D-[6,6-
2H2]glucose (98% enri-
ched; Cambridge Isotope Laboratories, http://www.isotope.com/
cil/index.cfm) was given as primed-continuous infusion [0 min to
5 min: 3.6 mg.(kg body weight)
21.(fasting plasma glucose in mg/
dl)/(90 mg/dl); 2115 min to +240 min 0.036 mg.min
21.(kg body
weight)
21] to assess Rd and EGP from +220 to +240 min. From
0t o+240 min, hyperinsulinemic-euglycemic clamp tests were
performed in 10 T2DM, 10 CONm and 11 CONy, while 7
CONy were only examined at baseline. Insulin (Actrapid; Novo,
Bagsvaerd, Denmark) was administered as primed-continuous
infusion [40 mU.(m body surface area)
22.min
21] and plasma
glucose was controlled by a variable 20% dextrose infusion, 2%
enriched with D-[6,6-
2H2]glucose according to the hot-glucose-
infusion protocol.
IMCL, PDE and other phosphorus metabolites were measured
at baseline and during insulin stimulation.
Magnetic Resonance Spectroscopy (MRS)
Measurements were performed on subjects lying supine inside a
3-Tesla MR spectrometer (Medspec S300-DBX; Bruker, Ettlin-
gen, Germany). The right lower leg positioned on a 10-cm circular
double resonant
1H/
31P surface coil (125.6/50.8 MHz) so that the
isocenter of the magnetic field was placed ,2 cm into the medial
head of the gastrocnemius muscle [22]. Phosphorus compounds
were measured from the ratio of the integrated peak intensities and
ß-ATP resonance intensity in spectra without inversion and
saturation (pulse length 150 ms/90u, 2k data, 8 averages, repetition
time of 15 s) assuming constant ATP concentrations of 5.5 mmol/
l muscle [22]. In human skeletal muscle, the peak between
inorganic phosphate (Pi) and phosphocreatine (PCr) represents the
Figure 1. Representative
31phosphorous magnetic resonance spectrum of skeletal muscle. Phosphorus compounds were measured from
the ratio of the integrated respective peak intensities and ß-ATP resonance intensity in spectra without inversion and saturation (pulse length 150 ms/
90u, 2k data, 8 averages, repetition time of 15 s) assuming a constant ATP concentration of 5.5 mmol/l muscle.
doi:10.1371/journal.pone.0021846.g001
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spho-ethanolamine/-choline, membrane-bound phospholipid me-
tabolites (Figure 1) [24]. Measurement of PDE has been validated
against chemical analysis employing preparations of muscular
ethanol-soluble PDE and exogenous glycerol-3-phosphorylcholine,
which confirmed that MRS-measured PDE represent the peak
resonating at 0.13 ppm [24].
Myocellular fATP [mmol.(g muscle
21).min
21] was measured
with
31P MRS employing the saturation transfer experiment to the
Pi/ATP exchange [22,25]. Glucose transport/-phosphorylation
was assessed from the increase in G6P during the clamp (DG6P).
IMCL in soleus muscle and liver fat content (HCL) were measured
by
1H MRS [22,26].
Analytical measurements
Plasma glucose was assessed by the glucose oxidase method
(Beckman, Fullerton, CA), FFA microfluorimetrically (Wako
Chem. USA Inc., Richmond, VA) and plasma insulin by
double-antibody radioimmunoassay (Pharmacia, Uppsala, Swe-
den). All other measurements were assessed in the routine lab.
Calculations and statistics
At baseline, rates of glucose appearance (Ra) were calculated by
dividing the tracer D-[6,6-
2H2]glucose infusion rate times tracer
enrichment by the percent of tracer enrichment in plasma and
subtracting the tracer infusion rate [27]. During the clamp, Ra was
calculated using Steele’s non-steady state equations [28]. EGP is
given as the difference between Ra and mean glucose infusion
rates.
Group data are presented as means and SD (Text) or SEM
(Figures) and compared with ANOVA and Tukey post-hoc testing
as appropriate. Within-group differences were assessed with two-
tailed t-tests. Linear correlations are Pearson product-moment
correlations. Partial correlation analysis was performed to study
the linear relationship between PDE and other variables after
excluding the effect of age, BMI or HbA1c. Differences were
considered significant at the 5-% level.
Results
All groups were matched for sex (50% female). BMI tended to
be (T2D: 2763; CONm: 2663; CONy: 2462 kg/m
2) and waist
circumference was higher in T2D and CONm (9769; 92617;
8068 cm, p,0.05 T2D vs. CONy). T2D and CONm were also
matched for age (5966; 5767; 2965 years, p,0.001 both vs.
CONy). T2D had greater fasting plasma glucose (8.961.7;
5.260.4; 4.860.7 mmol/l, p,0.001 vs. both CON groups) and
HbA1c (6.960.7; 5.560.3; 5.260.2 mmol/l, p,0.001 vs. both
CON), but comparable plasma FFA (0.5760.11; 0.4460.22;
0.4860.26 mmol/l) and low-density lipoprotein (LDL: 3.460.8;
3.860.9; 2.660.5 mmol/l).
During clamp steady-state (220–240 min), mean plasma
glucose, insulin and FFA were 5.560.5 mmol/l, 514696 pmol/l
and 0.0260.01 mmol/l without differences between groups. T2D
had ,33% and ,54% lower Rd than CONm and CONy;
CONm had ,31% lower Rd than CONy (5.760.5, 8.560.8,
12.461.0 mg.kg
21.min
21,p ,0.05, p,0.001 T2D vs. CONm
and CONy, p,0.005 CONm vs CONy). Insulin-suppressed EGP
reflecting hepatic insulin resistance was greater in T2D and
CONm (0.2360.05; 0.2260.09; 20.1460.09 mg.kg
21.min
21,
p,0.05 both vs. CONy).
Resting mitochondrial activity (fATP) was lower in T2D than in
CONy but comparable to CONm [22]. Stimulation by insulin
increased fATP in CONm and CONy but not in T2D and
unmasked impaired mitochondrial adaptation compared to
CONm [22].
In the fasted state, myocellular PDE contents were ,65% and
,47% higher in T2D and CONm compared to CONy, but not
different between T2D and CONm (Figure 2A). IMCL and
DG6P were comparable in all groups as reported [22] and did not
relate to PDE. Insulin stimulation did not affect PDE (basal vs.
insulin-stimulated: 2.860.8 vs. 2.960.7; 2.560.7 vs. 2.560.7;
CONy: 1.860.3 vs. 1.860.3 mmol/l), which were ,55% and
,38% higher in T2D and CONm compared to CONy (p,
0.001, p,0.05, Figure 2B). Changes in PDE did not relate to
DG6P.
PDE correlated negatively with fasting fATP (Figure 3A)a n d
insulin-mediated Rd (Figure 3B), but not with suppressed EGP
or insulin-stimulated fATP. PDE related positively to BMI
(Figure 3C), waist circumference (r=0.668, p,0.001), age
(r=0.656, p,0 . 0 0 1 ) ,H C L( r = 0 . 4 4 6 ,p ,0.01), HbA1c
(Figure 3D) and to fasting plasma glucose (r=0.629, p,
0.001) across all participants and within T2D (r=0.652,
r=0.653, p,0.05). There was no correlation between muscle
PDE and HbA1c in the pooled group of non-diabetic subjects.
PDE neither related to physical activity nor to plasma FFA, LDL
or IMCL. Correlations of PDE with fATP and Rd were
abolished after selective adjustment for either age, BMI or
HbA1c.
Figure 2. Phosphodiester (PDE; means ± SEM) content in 10
patients with type 2 diabetes (T2D, black columns), 10 age-
matched (CONm, grey columns) and 18 lean young controls
(CONy, empty columns) during fasting (A) and during insulin
stimulation (B).
doi:10.1371/journal.pone.0021846.g002
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Myocellular PDE levels are higher in middle-aged patients with
T2D and in age-matched controls than in young non-diabetic
humans. The relationships of PDE with insulin resistance and
mitochondrial function seem to depend mainly on aging, body
mass, but also glycemia.
The greater PDE in the middle-aged humans with or without
T2D is in accordance with its positive relationship to age as
reported previously [16], but confounding factors such as insulin
resistance or mitochondrial function were not identified before
[18]. Aging-related alterations of skeletal muscle could simply
result from reduced voluntary physical activity, but PDE - in line
with previous data [29] - did not relate to physical activity index.
All groups of the present study were sedentary and matched for
physical activity, but exercise testing was not performed. PDE has
been shown to be increased in professional road cyclists [30], but
to be significantly lower in sprinters than in sedentary and long-
distance runners [31]. Accordingly, a large PDE signal has been
reported as a sign of a larger relative content of type 1 fibers, i. e.
fast-to-slow twitch muscle transformation [32]. However, this
observation does not fit with increased PDE in aging or diabetic
subjects, who rather have increased [33,34,35] or normal fast
glycolytic fiber fractions [36,37]. Also, statins have been shown to
increase muscle PDE contents [17], but only four of our patients
with T2D were on statins and their PDE content was not different
from the other patients. Alternatively, aging-associated cumulative
oxidative damage may affect mitochondrial DNA and function
and lead to muscular degenerative processes [38]. Our T2D
showed lower fATP than both control groups during insulin
stimulation, while resting fATP was similarly lower in T2D and
CONm than in CONy [22].
In vivo and ex vivo measures reported lower oxidative capacity
in exercising and resting muscle of T2D patients which result from
intrinsic impairment and lower mitochondrial content
[3,4,39,40,41]. fATP, reflecting demand-driven resting mitochon-
drial activity, is lower in insulin-resistant elderly [21,22] and non-
diabetic offspring of T2D patients [42], but can be normal in T2D
compared to carefully matched non-diabetic humans [22,43].
Alternatively, abnormalities in insulin signaling may be the
primary events leading to impaired mitochondrial function, or
both phenomena may be mutually interrelated [44]. Of note,
lower mitochondrial content could be compensated for by greater
mitochondrial activity suggesting that insulin sensitivity and
mitochondrial function are not uniformly coupled [8,45,46,47].
Nevertheless, partial correlation analysis revealed that PDE
contents relate to aging independently of BMI and physical
activity, but not independently of fATP and insulin sensitivity.
Thus, the impact of aging on PDE is likely mediated by insulin
sensitivity and fATP.
Partial correlation analysis further identified PDE contents as an
independent indicator of glucometabolic control (HbA1c and
fasting plasma glucose) in T2D. Elevated PDE as observed in
muscle damage [17], pain syndromes [29] and muscle dystrophies,
has been previously attributed to oxidative stress [18,20,48]. One
might therefore speculate that glucotoxicity-induced chronic
Figure 3. Association between fasting myocellular phosphodiester (PDE) contents and flux through ATP synthase (fATP) (A), whole-
body glucose disposal (Rd) (B), body mass index (BMI) (C) and glycemic control (HbA1c) (D) in 10 patients with type 2 diabetes
(T2D, circles), 10 age-matched (CONm, squares) and 11–18 lean young controls (CONy, triangles) during fasting.
doi:10.1371/journal.pone.0021846.g003
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the lower fATP and insulin sensitivity in our T2D. This study
found a weak negative relationship between muscular PDE and
fATP, which disappeared upon adjusting for age, BMI and
HbA1c. While this does not exclude any role of mitochondrial
damage for raising PDE levels, it makes such mechanism rather
unlikely. However, fATP is only one feature of mitochondrial
function and in the present study mitochondrial content and
oxidative capacity were not measured. Furthermore, fATP as
assessed from the ATP saturation transfer experiment with
31P
MRS, reflects in vivo ATP synthase flux resulting from basal
energy demand and supplying processes and is therefore a
measure of resting mitochondrial activity. [49].
Muscular PDE related negatively to whole-body glucose
disposal but not specifically to insulin-mediated glucose trans-
port/phosphorylation and did not change during insulin stimula-
tion even in insulin sensitive humans. While PDE do not seem to
directly reflect insulin-dependent metabolic processes, its tight
relationship with BMI points to obesity-associated alterations such
as fatty acid composition of membrane phospholipids which may
influence insulin binding and action [50]. While lipid-induced
insulin resistance generally arises from increased plasma FFA and
intracellular lipids [51], this study found no association between
PDE, FFA and IMCL. Nevertheless, PDE are generated by
increased activities of phospholipases [16] which also yield
ceramides and diacylglycerols (DAG), possible mediators of insulin
resistance [52,53].
Some limitations need to be taken into account. First, no
biopsies were taken so that identification of individual components
of the PDE peak is not possible. However, the analysis of
individual compounds contributing to the PDE signal is difficult,
because ischemia during tissue handling will impact on analysis of
extracted tissue [24]. Second, no indicator of oxidative stress was
determined to analyse the possible role of PDE contents as a
biomarker of oxidative stress. However, available markers of
oxidative stress rely on various assumptions and do not offer direct
measures [6,54]. Finally, our T2D cohort comprised of normal
weight (n=4), overweight (n=4) and obese (n=2) Caucasians
yielding a mean BMI of 27 kg/m
2, which was not significantly
different but tended to be higher than in controls. While T2D
cohorts mostly have mean BMI exceeding 30 kg/m
2, other T2D
cohorts have lower mean BMI values, e. g. 28.5 kg/m
2 in the
ADVANCE study [55]. Thus, our T2D group might be suitable
and representative to analyse the impact of T2D per se on PDE
contents.
In conclusion, muscular PDE are higher in middle-aged patients
with or without T2D than in young non-diabetic humans. Body
mass and glycemia mainly determine the correlations of PDE with
resting mitochondrial activity, insulin resistance and age.
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